Ocugen Competitors and Similar CompaniesClear all
Ocugen's competitors and similar companies include Ambrx and Precigen.
 Ocugen Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases |  Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2013 | Founding Date 2003 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Malvern, US HQ | Locations San Diego, US HQ | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 84425% increase | Employees 70 | Employees 601 |
Valuation ($) | Valuation ($) 292.1 m | Valuation ($) 1.8 b | Valuation ($) 246.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) $4.4m (FY, 2025) | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) $9.7m (FY, 2025) |
Net income | Net income ($67.8m) (FY, 2025) | Net income ($78m) (FY, 2022) | Net income ($250.6m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 347.9m | Total funding raised $ 379m |
For sources of this data, please see the company profile
View Company Profiles
Ambrx
HQ
San Diego, US
Employees
70
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company